Transcriptomic profiling of LCD-treated splenic B cells revealed significant NF-κB signaling modulation, suggesting its pivotal role in mediating LCD’s therapeutic effects and highlighting this pathway as a potential therapeutic target (17). Here, NFKB1 is linked to lattice corneal dystrophy type I.